The PACAP Receptor: A Novel Target for Migraine Treatment

Neurotherapeutics

Volumn 7, Issue 2, 2010, Pages 191-196

  Schytz, Henrik W ^a   Olesen, Jes ^a   Ashina, Messoud ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

drug targets; human experimental headache models; mast cell degranulation; Migraine; trigeminal nociceptive system; vasodilatation

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; NEUROPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ARTICLE; BRAIN BLOOD VESSEL; DRUG TARGETING; HUMAN; MAST CELL DEGRANULATION; MIGRAINE; NOCICEPTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SENSORY NERVE CELL; SIGNAL TRANSDUCTION; TRIGEMINAL NERVE; VASODILATATION;

ANIMALS; HEMODYNAMICS; HUMANS; MIGRAINE DISORDERS; MODELS, BIOLOGICAL; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; VASODILATOR AGENTS;

EID: 77953429357     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2010.02.003     Document Type: Article

References (66)

1. Andlin-Sobocki P., Jönsson B., Wittchen H.U., and Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 12 Suppl 1 (2005) 1-27
2. Olesen J., Tfelt-Hansen P., and Ashina M. Finding New drug targets for the treatment of migraine attacks. Cephalalgia 29 (2009) 909-920
3. Olesen J., Burstein R., Ashina M., and Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 8 (2009) 679-690
4. Uddman R., Tajti J., MÖller S., Sundler F., and Edvinsson L. Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res 826 (1999) 193-199
5. Edvinsson L., Elsås T., Suzuki N., Shimizu T., and Lee T.J. Origin and co-localization of nitric oxide synthase, CGRP, PACAP, and VIP in the cerebral circulation of the rat. Microsc Res Tech 53 (2001) 221-228
6. Nozaki K., Moskowitz M.A., Maynard K.I., et al. Possible origins and distribution of immunoreactive nitric oxide synthase-containing nerve fibers in cerebral arteries. J Cereb Blood Flow Metab 13 (1993) 70-79
7. Suzuki N., and Hardebo J.E. Anatomical basis for a parasympathetic and sensory innervation of the intracranial segment of the internal carotid artery in man: possible implication for vascular headache. J Neurol Sci 104 (1991) 19-31
8. Lassen L.H., Haderslev P.A., Jacobsen V.B., Iversen H.K., Sperling B., and Olesen J. CGRP may play a causative role in migraine. Cephalalgia 22 (2002) 54-61
9. Thomsen L.L., Kruuse C., Iversen H.K., and Olesen J. A nitric oxide donor triggers genuine migraine attacks. Eur J Neurol 1 (1994) 73-80
10. Schytz H.W., Birk S., Wienecke T., Kruuse C., Olesen J., and Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132 (2009) 16-25
11. Miyata A., Arimura A., Dahl R.R., et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164 (1989) 567-574
12. Vaudry D., Falluel-Morel A., Bourgault S., et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61 (2009) 283-357
13. Arimura A., Somogyvári-Vigh A., Miyata A., Mizuno K., Coy D.H., and Kitada C. Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129 (1991) 2787-2789
14. Ghatei M.A., Takahashi K., Suzuki Y., Gardiner J., Jones P.M., and Bloom S.R. Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. J Endocrinol 136 (1993) 159-166
15. Hannibal J., Mikkelsen J.D., Clausen H., Holst J.J., Wulff B.S., and Fahrenkrug J. Gene expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat hypothalamus. Regul Pept 55 (1995) 133-148
16. Mikkelsen J.D., Hannibal J., Fahrenkrug J., Larsen P.J., Olcese J., and McArdle C. Pituitary adenylate cyclase activating peptide-38 (PACAP-38), PACAP-27, and PACAP related peptide (PRP) in the rat median eminence and pituitary. J Neuroendocrinol 7 (1995) 47-55
17. Tajti J., Uddman R., Möller S., Sundler F., and Edvinsson L. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 76 (1999) 176-183
18. Uddman R., Tajti J., Hou M., Sundler F., and Edvinsson L. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 22 (2002) 112-116
19. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., and Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52 (2000) 269-324
20. Mulder H., Uddman R., Moller K., et al. Pituitary adenylate cyclase activating polypeptide is expressed in autonomic neurons. Regul Pept 59 (1995) 121-128
21. Harmar A.J., Arimura A., Gozes I., et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50 (1998) 265-270
22. Dickson L., and Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol Ther 121 (2009) 294-316
23. Dickinson T., and Fleetwood-Walker S.M. VIP and PACAP: very important in pain?. Trends Pharmacol Sci 20 (1999) 324-329
24. Knutsson M., and Edvinsson L. Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport 13 (2002) 507-509
25. Zagami A.S., Edvinsson L., HK L., and Goadsby P.J. Stimulation of the superior sagittal sinus causes extracranial release of PACAP. Cephalalgia 15 Suppl 14 (1995) 109
26. Yarnitsky D., Goor-Aryeh I., Bajwa Z.H., et al. 2003 Wolff Award: Possible parasympathetic contributions to peripheral and central sensitization during migraine. Headache 43 (2003) 704-714
27. Maizels M., Scott B., Cohen W., and Chen W. Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA 276 (1996) 319-321
28. Rozniecki J.J., Dimitriadou V., Lambracht-Hall M., Pang X., and Theoharides T.C. Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo. Brain Res 849 (1999) 1-15
29. Iversen H.K., Nielsen T.H., Olesen J., and Tfelt-Hansen P. Arterial responses during migraine headache. Lancet 336 (1990) 837-839
30. Friberg L., Olesen J., Iversen H.K., and Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 338 (1991) 13-17
31. Uddman R., Goadsby P.J., Jansen I., and Edvinsson L. PACAP, a VIP-like peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. J Cereb Blood Flow Metab 13 (1993) 291-297
32. Seki Y., Suzuki Y., Baskaya M.K., et al. The effects of pituitary adenylate cyclase-activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs. Eur J Pharmacol 275 (1995) 259-266
33. Boni L.J., Ploug K.B., Olesen J., Jansen-Olesen I., and Gupta S. The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. Cephalalgia 29 (2009) 837-847
34. Birk S., Sitarz J.T., Petersen K.A., et al. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 140 (2007) 185-191
35. Baun M., Olesen J., and Jansen-Olesen I. Expression studies and pharmacological characterization of VIP and PACAP receptors in the cerebral circulation of the rat. Cephalalgia 29 Suppl 1 (2009) 133 (abstract PO316)
36. Baun M., Chan K.Y., Olesen J., Jansen-Olesen I., Gupta S., and Maassen Van Den Brink A. Pharmacological characterization and mRNA expression studies of VIP and PACAP receptors in human coronary arteries. Cephalalgia 29 Suppl 1 (2009) 132 (abstract PO315)
37. Levy D. Migraine pain, meningeal inflammation, and mast cells. Curr Pain Headache Rep 13 (2009) 237-240
38. Theoharides T.C., Donelan J., Kandere-Grzybowska K., and Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev 49 (2005) 65-76
39. Heatley R.V., Denburg J.A., Bayer N., and Bienenstock J. Increased plasma histamine levels in migraine patients. Clin Allergy 12 (1982) 145-149
40. Lassen L.H., Thomsen L.L., and Olesen J. Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. Neuroreport 6 (1995) 1475-1479
41. Levy D., Burstein R., Kainz V., Jakubowski M., and Strassman A.M. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 130 (2007) 166-176
42. Zhang X.C., Strassman A.M., Burstein R., and Levy D. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J Pharmacol Exp Ther 322 (2007) 806-812
43. Kulka M., Sheen C.H., Tancowny B.P., Grammer L.C., and Schleimer R.P. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 123 (2008) 398-410
44. Odum L., Petersen L.J., Skov P.S., and Ebskov L.B. Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res 47 (1998) 488-492
45. Ottosson A., and Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 17 (1997) 166-174
46. Dickson L., Aramori I., McCulloch J., Sharkey J., and Finlayson K. A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology 51 (2006) 1086-1098
47. Levy D., and Strassman A.M. Distinct sensitizing effects of the cAMP-PKA second messenger cascade on rat dural mechanonociceptors. J Physiol 538 (2002) 483-493
48. Ingram S.L., and Williams J.T. Modulation of the hyperpolarization-activated current (Ih) by cyclic nucleotides in guinea-pig primary afferent neurons. J Physiol 492 Pt 1 (1996) 97-106
49. 1 receptor antagonists inhibit activation of the parasympathetic outflow to the cranial vasculature to prevent autonomic responses and neuronal firing in the trigeminocervical complex. Cephalalgia 29 Suppl 1 (2009) 130 (abstract PO310)
50. Tajti J., Uddman R., and Edvinsson L. Neuropeptide localization in the "migraine generator" region of the human brainstem. Cephalalgia 21 (2001) 96-101
51. Basbaum A.I., Clanton C.H., and Fields H.L. Three bulbospinal pathways from the rostral medulla of the cat: an autoradiographic study of pain modulating systems. J Comp Neurol 178 (1978) 209-224
52. Weiller C., May A., Limmroth V., et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1 (1995) 658-660
53. Hashimoto H., Shintani N., and Baba A. New insights into the central PACAPergic system from the phenotypes in PACAP- and PACAP receptor-knockout mice. Ann N Y Acad Sci 1070 (2006) 75-89
54. Zhang Y., Malmberg A.B., Yaksh T.L., Sjölund B., Sundler F., and Håkanson R. Capsaicin-evoked release of pituitary adenylate cyclase activating peptide (PACAP) and calcitonin gene-related peptide (CGRP) from rat spinal cord in vivo. Regul Pept 69 (1997) 83-87
55. Mabuchi T., Shintani N., Matsumura S., et al. Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain. J Neurosci 24 (2004) 7283-7291
56. Ji R.R., Kohno T., Moore K.A., and Woolf C.J. Central sensitization and LTP: do pain and memory share similar mechanisms?. Trends Neurosci 26 (2003) 696-705
57. 1 receptor. Neuroreport 12 (2001) 2215-2219
58. Davis-Taber R., Baker S., Lehto S.G., et al. Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states. J Pain 9 (2008) 449-456
59. Ohsawa M., Brailoiu G.C., Shiraki M., Dun N.J., Paul K., and Tseng L.F. Modulation of nociceptive transmission by pituitary adenylate cyclase activating polypeptide in the spinal cord of the mouse. Pain 100 (2002) 27-34
60. Hansen J.M., Sitarz J., Birk S., et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 26 (2006) 992-1003
61. Rahmann A., Wienecke T., Hansen J.M., Fahrenkrug J., Olesen J., and Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28 (2008) 226-236
62. Schytz H.W., Holst H., Arendt-Nielsen L., Olesen L., and Ashina M. Cutaneous nociception and neurogenic inflammation evoked by VIP and PACAP38: a human experimental study. Cephalalgia 29 12 (2009) 1358 (abstract LBPO08)
63. Banks W.A., Kastin A.J., Komaki G., and Arimura A. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther 267 (1993) 690-696
64. Birk S., Kruuse C., Petersen K.A., Tfelt-Hansen P., and Olesen J. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia 26 (2006) 1304-1309
65. 8-37, a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 150 (2007) 633-640
66. Ho T.W., Mannix L.K., Fan X., et al. MK-0974 Protocol 004 Study Group. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70 (2008) 1304-1312